Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy

Br J Haematol. 2016 Nov;175(4):735-737. doi: 10.1111/bjh.13879. Epub 2015 Dec 18.

Authors

Sylvain Garciaz¹, Stephanie Harel², Sandy Amorim², Réda Bouabdallah¹, Catherine Thieblemont², Pauline Brice²

Affiliations

¹ Department of Haematology, Institut Paoli-Calmettes, Marseille, France.
² Department of Haematology, APHP, Hôpital Saint-Louis, Paris, France.

PMID: 26685097
DOI: 10.1111/bjh.13879

No abstract available

Keywords: Nodular lymphocyte predominant Hodgkin lymphoma; Rituximab.

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bleomycin / pharmacology
Bleomycin / therapeutic use
Dacarbazine / pharmacology
Dacarbazine / therapeutic use
Doxorubicin / pharmacology
Doxorubicin / therapeutic use
Female
Hodgkin Disease / drug therapy*
Hodgkin Disease / pathology
Humans
Lymphocytes / pathology*
Male
Middle Aged
Rituximab / pharmacology
Rituximab / therapeutic use*
Vinblastine / pharmacology
Vinblastine / therapeutic use
Young Adult

Substances

Bleomycin
Rituximab
Vinblastine
Dacarbazine
Doxorubicin

Supplementary concepts

ABVD protocol